KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Other Gross PP&E Adjustments (2016 - 2025)

BeOne Medicines (ONC) has disclosed Other Gross PP&E Adjustments for 11 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 250.89% to $1.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 billion, a 250.89% increase, with the full-year FY2025 number at $1.7 billion, up 250.89% from a year prior.
  • Other Gross PP&E Adjustments was $1.7 billion for Q4 2025 at BeOne Medicines, up from $1.7 billion in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $1.7 billion in Q4 2025 to a low of -$29.8 million in Q4 2023.
  • A 5-year average of $455.1 million and a median of $263.3 million in 2022 define the central range for Other Gross PP&E Adjustments.
  • Peak YoY movement for Other Gross PP&E Adjustments: crashed 116.73% in 2024, then surged 4545.86% in 2025.
  • BeOne Medicines' Other Gross PP&E Adjustments stood at $205.8 million in 2021, then skyrocketed by 46.02% to $300.5 million in 2022, then plummeted by 109.9% to -$29.8 million in 2023, then surged by 1752.62% to $491.8 million in 2024, then skyrocketed by 250.89% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Other Gross PP&E Adjustments are $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.2 billion (Q2 2025).